Aeglea BioTherapeutics, Inc. (AGLE) |
|
11.49 0.07 (0.61%)
|
09-27 16:00 |
|
Open: |
11.28 |
Pre. Close: |
11.42 |
|
High:
|
11.74 |
Low:
|
11.06 |
|
Volume:
|
15,098 |
Market Cap:
|
47(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:17:32 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 16.52 One year: 19.36 |
| Support: |
Support1: 10.22 Support2: 8.5 |
| Resistance: |
Resistance1: 14.15 Resistance2: 16.57 |
| Pivot: |
12.86  |
| Moving Average: |
MA(5): 11.59 MA(20): 13.29
MA(100): 9.93 MA(250): 11.76 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 19.8 %D(3): 21.7 |
| RSI: |
RSI(14): 39.8 |
| 52-week: |
High: 39 Low: 2.65 |
| Average Vol(K): |
3-Month: 55 (K) 10-Days: 37 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AGLE ] has closed above bottom band by 24.9%. Bollinger Bands are 26.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.32 - 12.4 |
12.4 - 12.47 |
|
Low:
|
10.86 - 10.94 |
10.94 - 11 |
|
Close:
|
11.22 - 11.34 |
11.34 - 11.44 |
|
Company Description |
|
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. |
Headline News |
Wed, 13 Sep 2023
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Receives Average ... - MarketBeat
Thu, 07 Sep 2023
Aeglea BioTherapeutics Announces Reverse Stock Split - PR Newswire
Tue, 05 Sep 2023
Aeglea BioTherapeutics Expands Executive Leadership Team with ... - PR Newswire
Fri, 11 Aug 2023
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial ... - PR Newswire
Thu, 27 Jul 2023
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to ... - PR Newswire
Thu, 22 Jun 2023
Is Aeglea Bio Therapeutics Inc (AGLE) Stock About to Get Hot Thursday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
2.65e+006 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
85 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.0349e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-16 |
|
Return on Assets (ttm)
|
695.2 |
|
Return on Equity (ttm)
|
-73.2 |
|
Qtrly Rev. Growth
|
1.23e+006 |
|
Gross Profit (p.s.)
|
3.99 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-103557 |
|
Qtrly Earnings Growth
|
-76.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-67 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.46 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
61600 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
